An evaluation of the 4 mg nicotine mint lozenge for the relief of cognitive impairment associated with nicotine withdrawal.

Registry ID

EUCTR2005-005307-42

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

GlaxoSmithKline Consumer Healthcare

Start date

2006-01-03

Completion date

2006-04-20

Last update

2026-08-16

Conditions

• Nicotine dependence.

Summary

The primary objective of this study is to compare the effect of the 4 mg nicotine mint lozenge to placebo on ability to concentrate, as measured by the Rapid Visual Information Processing (RVIP) test.

Locations

• , , UK

View on source registry